Holly McDonald

We spoke with Farrukh Awan, MD, University of Texas Southwestern Medical Center, about some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years. "At some point, we hope to have a strategy that would cure or permanently eliminate the disease in a small subset of our patients. However, it's hard to quantify cures in CLL because the remission period is so long that we have to follow patients for a long period of time to definitively say that the cancer has completely been eliminated and will not come back after stopping therapy," said Dr Awan. Watch the full interview here: https://lnkd.in/dy4v4HJz #JournalOfClinicalPathways #CLL #ChronicLymphocyticLeukemia #CancerCare

1

Oncology Policy Summit on Advancing Diversity, Equity, and Inclusion in the Cancer Workforce - National Comprehensive Cancer Network® (NCCN®) #Oncology #Cancer #EquityInCancerCare #InclusionInHealthcare #NCCN #CancerWorkforce #OncoDaily #CancerResearch #AdvancingDiversity #OncologyLeadership

25

Streamlining the regulatory process for rare disease therapies could transform the treatment landscape. Learn more about the establishment of the FDA Center of Excellence for Rare Diseases and why it’s a crucial step toward addressing the unique regulatory challenges of rare diseases. EveryLife Foundation for Rare Diseases

5